| Kenneth A. DiPietro |
Kenneth A. DiPietro is the founder of Alioth, Inc. (founded in 2018) where he holds the title of Director. He is currently the Chief Human Resources Officer at Cerevel Therapeutics Holdings, Inc. since 2019. Mr. DiPietro received his undergraduate degree from Cornell University. |
| Susan Altschuller |
Dr. Susan Altschuller is an Independent Director at Mural Oncology Plc, a Chief Financial Officer at Cerevel Therapeutics Holdings, Inc., a Chief Financial Officer at Cerevel Therapeutics, Inc. and a Founding Member at HNRNP Family Foundation. She is on the Board of Directors at Mural Oncology Plc and Vestaron Corp. Dr. Altschuller was previously employed as a Chief Financial Officer & Senior Vice President by ImmunoGen, Inc., a Head-Enterprise Finance by Alexion Pharmaceuticals, Inc., a Head-Investor Relations by Biogen, Inc., and a Head-Investor Relations by Bioverativ, Inc. She received her undergraduate degree from Tulane University (Louisiana), an MBA from MIT Sloan School of Management and a doctorate degree from Illinois Institute of Technology. |
| Kathleen Tregoning |
Kathleen Tregoning is currently an Independent Director at Spero Therapeutics, Inc. since 2021 and the Chief Corporate Affairs Officer at Cerevel Therapeutics Holdings, Inc. since 2020. Previously, she served as the Executive Vice President-External Affairs at Sanofi from 2017 to 2020. She also held the position of Senior Vice President-Corporate Affairs at Biogen France SAS. Ms. Tregoning completed her undergraduate degree at Stanford University and her graduate degree at Harvard Kennedy School of Government. |
| Paul Burgess |
Paul Burgess is currently the Chief Business Development Officer at Cerevel Therapeutics Holdings, Inc. He previously worked as the Director-Intellectual Property at Logical Therapeutics, Inc., as well as the In-House Counsel at Johnson & Johnson. From 2008 to 2015, he served as the Vice President-Intellectual Property at DNIB Unwind, Inc. He also held the position of Secretary, Chief Operating & Legal Officer at Translate Bio, Inc. from 2019 to 2021. Additionally, he worked as the Head-Intellectual Property at Civitas Therapeutics, Inc. from 2011 to 2015 and as the Vice President-Intellectual Property at Scholar Rock, Inc. from 2015 to 2016. He has also held the role of Head-Legal at TransForm Pharmaceuticals, Inc. in the past. Mr. Burgess obtained his undergraduate degree from Merrimack College in 1995. He furthered his education at Northeastern University, earning graduate degrees in 2002 and 1999. |
| Mark Bodenrader |
Mark Bodenrader is currently the Chief Accounting Officer & Senior Vice President at Cerevel Therapeutics Holdings, Inc. He previously worked as a Controller at Biogen, Inc. and as an Assistant Controller at Cabot Industrial Trust from 1998 to 2002. He also served as the Head-Internal Audit at Heritage Property Investment Trust, Inc. Additionally, Mark worked as a Manager-Assurance & Business Advisory Services at Grant Thornton LLP from 2003 to 2004. Mr. Bodenrader completed his undergraduate degree at Merrimack College. |
| John Renger |
John Renger is currently the Chief Scientific Officer at Cerevel Therapeutics Holdings, Inc. He previously worked as the Vice President-Research & Development at Imbrium Therapeutics LP. Prior to that, he was the Head-Clinical Research & Transitional Medicine at Purdue Pharma LP from 2016 to 2018. From 2001 to 2016, he held the position of Associate Vice President at Merck & Co., Inc. Dr. Renger obtained his undergraduate and doctorate degrees from the University of Iowa. |
| Raymond Sanchez |
Raymond Sanchez is currently the Executive Co-Chairman at the International Society for CNS Drug Development, the Director at Yale School of Medicine, the Chief Medical Officer at Cerevel Therapeutics Holdings, Inc., and a Trustee at the Connecticut Mental Health Center Foundation. Previously, he held positions as the Chief Medical Officer at Avanir Pharmaceuticals, Inc. and as the Senior Vice President-Global Clinical Development at Otsuka Pharmaceutical Development & Commercialization, Inc. Dr. Sanchez received his undergraduate degree from Northwestern University, his doctorate from Feinberg School of Medicine, and another undergraduate degree from Weinberg College of Arts & Sciences. |
| Scott M. Akamine |
Scott M. Akamine is currently the Secretary & Chief Legal Officer at Cerevel Therapeutics Holdings, Inc. He previously worked as an Attorney at Latham & Watkins LLP, General Counsel & Associate General Counsel at CoreLogic, Inc., Secretary & General Counsel at AEON Biopharma Sub, Inc., and Secretary & General Counsel at Incipio LLC. Akamine received his undergraduate degree from Chapman University and his graduate degree from Pepperdine University School of Law. |
| N. Anthony Coles |
N. Anthony Coles founded Yumanity, Inc. in 2014, where he worked as Executive Chairman from 2019 to 2020. Dr. Coles also founded Yumanity Therapeutics, Inc., where he worked as Chairman from 2020 to 2021. Dr. Coles also currently works at Cerevel Therapeutics LLC, as Executive Chairman & Chief Executive Officer from 2019, Cerevel Therapeutics Holdings, Inc., as Chairman from 2023, Regeneron Pharmaceuticals, Inc., as Independent Director from 2017, and various other companies. Dr. Coles also formerly worked at NPS Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2005 to 2008, Onyx Pharmaceuticals, Inc., as President & Chief Executive Officer in 2013, Trate Enterprises, LLC, as Chairman & Chief Executive Officer from 2013 to 2014, and various other companies. Dr. Coles received his doctorate degree from Duke University, graduate degree from Harvard University, and undergraduate degree from The Johns Hopkins University. |
| Ronald C. Renaud |
Ronald C. Renaud is currently the President, Chief Executive Officer & Director at Cerevel Therapeutics Holdings, Inc. He is also the Independent Chairman at Axial Therapeutics, Inc., Chairman at Upstream Bio, Inc., Director at Jnana Therapeutics, Inc., Trustee at St. Anselm College, and Member-Overseers Board at Newton-Wellesley Hospital Corp. Additionally, he serves as a Senior Advisor at Bain Capital Life Sciences LP. In his former positions, Mr. Renaud served as the President, CEO, CFO & Director at Idenix Pharmaceuticals LLC from 2007 to 2014. He was the Chairman & Chief Executive Officer at Translate Bio, Inc. from 2014 to 2021 and the Chairman at Ikena Oncology, Inc. from 2018 to 2022. He also held positions as a Managing Director at Bear, Stearns & Co., Inc. and Charles Schwab & Co., Inc. He served as an Independent Director at Chimerix, Inc. from 2014 to 2020, an Independent Class Director at PTC Therapeutics, Inc. from 2014 to 2017, and an Independent Director at Akebia Therapeutics, Inc. from 2014 to 2018. Additionally, he was a Board of Directors member at the American Liver Foundation of Northern California from 2012 to 2014. Mr. Renaud received his undergraduate degree from St. Anselm College in 1990 and an MBA from USC Marshall School of Business in 1999. |
| Christopher Riley Gordon |
Christopher Riley Gordon is currently a Director at Quintiles Transnational Corp., Carelon Behavioral Health Holdings LLC, Bain Capital Private Equity LP, CRC Health Group, Inc., Physio-Control, Inc., Innovacare Us LP, Air Medical Group Holdings, Inc., Year Up, Inc., Boston Medical Center Health Plan, Inc., Healthcare Private Equity Association, Tenacity, Inc., Boston Medical Center Foundation, BNVC Group Holdings, Inc., Kestra Medical Technologies, Inc., Aveanna Healthcare LLC, Cerevel Therapeutics LLC, Cerevel Therapeutics Holdings, Inc., BMC HealthNet Plan, Cerevel Therapeutics, Inc., Aveanna Healthcare Holdings, Inc., and BCPE Osprey Holdings LP. He is also a Trustee at Dana-Farber Cancer Institute, Inc. Previously, Mr. Gordon served as the Chairman at Notre Dame Intermedica Participaçoes SA and Notre Dame Intermédica Saúde SA. He was also a Director at FIS Capital Markets US LLC (Pennsylvania), U.S. Renal Care, Inc., Quintiles Transnational Holdings, Inc., Lake Region Medical, Inc., Hospital Corporation of America, CRC Health Corp., HCA Healthcare, Inc., Acadia Healthcare Co., Inc., Innovacare, Inc., Beacon Health Options, Inc., Surgery Partners, Inc., QuVa Pharma, Inc., IQVIA Holdings, Inc., and Waystar Holding Corp.Mr. Gordon obtained an MBA from Harvard Business School and completed his undergraduate studies at Harvard College. |
| Gabrielle G. Greene-Sulzberger |
Gabrielle G. Greene-Sulzberger founded Fontis Partners LP in 2009, where she worked as General Partner from 2009 to 2017. Ms. Greene-Sulzberger also currently works at Sesame Workshop, as Chairman, True Food Kitchen Investco LLC, as Chairman from 2019, auxmoney GmbH, as Chairman, and various other companies. Ms. Greene-Sulzberger also formerly worked at Johnson Products Co., Inc., as Chief Executive Officer from 2011 to 2013, Teneo Holdings LLC, as Chairman-ESG Practice, Teneo Consulting LLC, as Chairman-ESG Practice, and various other companies. Ms. Greene-Sulzberger received her undergraduate degree in 1985 from Princeton University, Masters Business Admin degree in 1987 from Harvard Business School, graduate degree from Harvard Law School, and undergraduate degree from Woodrow Wilson School of Public & International Affairs. |
| Deborah Baron |
Deborah Baron is currently the Chief Executive Officer at Amplyx Pharmaceuticals, Inc. She also holds positions as the Director at Seagen Inc., the President & Director at Trillium Therapeutics ULC, and the Independent Director at Cerevel Therapeutics Holdings, Inc. Additionally, she is a Director at Cerevel Therapeutics, Inc. Previously, she worked as a Director at Global Blood Therapeutics, Inc. and as the Senior VP-Worldwide Business Development at Pfizer Inc. Ms. Baron completed her undergraduate degree at the Massachusetts Institute of Technology and holds an MBA from the MIT Sloan School of Management. |
| Douglas Ernest Giordano |
Douglas Ernest Giordano is currently the Chief Executive Officer at Anacor Pharmaceuticals LLC, the President, Treasurer & Director at Array BioPharma, Inc., the President & Director at FoldRx. Pharmaceuticals LLC, the Director at ViiV Healthcare Ltd., the Managing Director at Perceptive Advisors (Private Equity), the Director at Cerevel Therapeutics LLC, the Independent Director at Cerevel Therapeutics Holdings, Inc., the Director at Cerevel Therapeutics, Inc., the Independent Director at Panacea Acquisition Corp. II, the President at Encysive Pharmaceuticals, Inc., the Vice President at Icagen, Inc., and an Advisor at New Rhein Healthcare Investors. Previously, Mr. Giordano worked as the Director at ICU Medical, Inc., the Director at KP Pharmaceuticals LLC, the Director at Zoetis, Inc., the President, Treasurer & Director at Medivation LLC (California), the Director at Viatris, Inc., and the Senior VP-Worldwide Business Development at Pfizer Inc. He also served as the President at Serenex, Inc.Mr. Giordano received his undergraduate degree from Duke University and his MBA from Johnson Graduate School of Management. |
| Ruth McKernan |
Ruth McKernan is the founder of Cumulus Neuroscience Ltd. She currently holds multiple positions including Chairman at Astronautx Ltd., Director at Neusentis, Inc., Director at The Medical Research Council, Director at The Bioindustry Association, Independent Director at Cerevel Therapeutics Holdings, Inc., Director at Cerevel Therapeutics, Inc., Venture Partner at SV Health Investors LLP, Member of the Society For Neuroscience, Member of the British Pharmacological Society, and Trustee at Alzheimer’s Research UK. Previously, she served as the Chief Executive Officer at Innovate UK from 2015 to 2018 and held positions at Pfizer Inc. and Cancer Research UK. Dr. McKernan obtained a doctorate degree from the University of London and an undergraduate degree from King's College London. |
| Deval L. Patrick |
Deval L. Patrick is the founder of TogetherFUND Ltd., which was founded in 2020. He served as the Chairman of the company from 2020 to 2021. Mr. Patrick currently holds multiple positions. He is the Co-Chairman of American Bridge 21St Century Foundation. He is also an Independent Director at American Well Corp., Twilio, Inc., Social Finance, Inc. (Massachusetts), Toast, Inc., SpringWorks Therapeutics LLC, and Cityblock Health, Inc. Additionally, he is a Professor at Harvard Kennedy School of Government. He serves as a Senior Advisor at Bain Capital Double Impact LP and a Board Advisor at Higher Ground Labs Management LLC. Mr. Patrick has held several former positions. He served as the Chairman of Massachusetts Port Authority in 2011. From 2000 to 2004, he was a Director at Coca-Cola Enterprises, Inc. He also served as a Director at Reebok International Ltd. He was an Independent Director at American Well Corp. from 2015 to 2019. He served as a Director at Whitehead Institute for Biomedical Research. He was an Independent Director at Global Blood Therapeutics, Inc. from 2015 to 2019 and again from 2020 to 2022. He was an Independent Director at Springworks Therapeutics, Inc. from 2017 to 2019. He served as a Director at United Airlines, Inc. He was an Independent Director at Environmental Impact Acquisition Corp. from 2021 to 2022. He held the position of General Counsel & Vice President at Chevron Corp. He was the Secretary, Executive VP & General Counsel at The Coca-Cola Co. from 2001 to 2005. He was a Partner at Texaco, Inc. He served as a Managing Partner-Double Impact Fund at Bain Capital LP from 2015 to 2019. He was the Governor of the State of Massachusetts from 2007 to 2015. Mr. Patrick received his graduate degree from Harvard Law School in 1982 and his undergraduate degree from Harvard College in 1978. |
| Marijn E. Dekkers |
Marijn E. Dekkers is the founder and currently holds the position of Chairman at Novalis Lifesciences LLC, which was founded in 2017. He is also currently serving as Chairman at AgBiome INC, Ginkgo Bioworks, Inc., eTheRNA immunotherapies NV, Unilever International Holdings NV, Ginkgo Bioworks Holdings, Inc., Georgetown University, Foundation for the National Institutes of Health, Inc., Enko Chem, Inc., Flywheel Exchange, Inc., Cerevel Therapeutics LLC, Q-SI Operations, Inc., Vizgen, Inc., Cerevel Therapeutics Holdings, Inc., Animol Discovery, Cerevel Therapeutics, Inc., The Business Roundtable, The Business Council, and Bundesverband der Deutschen Industrie e.V. He has previously held the position of Chairman-Management Board & CEO at Bayer AG from 2010 to 2016, Chief Executive Officer at Bayer HealthCare AG in 2010, President, Chief Executive Officer & Director at Thermo Fisher Scientific, Inc. from 2000 to 2009, Independent Director at GE Aerospace from 2012 to 2018, Director at Biogen, Inc. from 2007 to 2009, Non-Executive Director at Unilever Plc from 2016 to 2020, Independent Director at Quanterix Corp. from 2017 to 2021, Non-Executive Director at Unilever NV from 2016 to 2020, and President at Verband der Chemischen Industrie eV from 2011 to 2016. Dr. Dekkers has a graduate and doctorate degree from Technische Universiteit Eindhoven and an undergraduate degree from Radboud University Nijmegen. |
| Suneet Varma |
Suneet Varma is an Independent Director at Cerevel Therapeutics Holdings, Inc. He is also a Director at Cerevel Therapeutics, Inc. and a Trustee at Drew University and Kent Place School, Inc. Previously, he served as the President-US Oncology Business Unit at Pfizer Inc. and held positions as a Director at The Advertising Council, Inc. and President & General Manager at Pfizer Consumer Healthcare (United Kingdom). Mr. Varma completed his undergraduate degree at Tufts University and earned an MBA from Harvard Business School. |
| Adam M. Koppel |
Adam M. Koppel is currently serving as an Independent Director at Solid Biosciences, Inc. and as a Managing Director at Bain Capital Life Sciences LP. He is also an Independent Director at Foghorn Therapeutics, Inc. Additionally, he holds director positions at Cardurion Pharmaceuticals LLC, Cerevel Therapeutics LLC, Cerevel Therapeutics Holdings, Inc., Areteia Therapeutics, Inc., Newton-Wellesley Hospital Corp., and Museum of Science. Furthermore, he is a Trustee at Newton-Wellesley Health Care System, Inc. In his former roles, Dr. Koppel served as the Chairman of BCLS Acquisition Corp. He was also a Managing Director at Bain Capital Public Equity LP and held the position of Independent Director at PTC Therapeutics, Inc., ViaCyte, Inc., Dicerna Pharmaceuticals, Inc., Trevena, Inc., Temple Beth Elohim, and Aptinyx, Inc. Additionally, he served as the Chief Strategy Officer & EVP-Business Development at Biogen, Inc. and as an Associate Principal at McKinsey & Co., Inc. He also held a position as Principal at Altus Pharmaceuticals, Inc.Dr. Koppel received his undergraduate and graduate degrees from Harvard University. He also holds an MBA from The Wharton School of the University of Pennsylvania. Furthermore, he obtained a doctorate degree from the University of Pennsylvania Medical Center. |
